Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04443569 · ClinicalTrials.gov registry record · Phase 3

Lidocaine Patches After Cesarean Section

A Phase 3 study of Opioid Use and Postoperative Pain, sponsored by Yale University.

Completed
Registry status
Phase 3
Development phase
93
Enrollment target
1
Study location

NCT04443569 is a Phase 3 study of Opioid Use and Postoperative Pain that has completed, run by Yale University. The registered enrollment target is 93 participants, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04443569, a Phase 3 study of Opioid Use and Postoperative Pain, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 3
Development phase
93 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to investigate the impact of using lidocaine patches after cesarean section on pain control and opioid use in the immediate post-operative period. The hypothesis is the use of lidocaine patches in the immediate post-operative period will lead to a decrease in the visual analog pain score compared to women who do not use a lidocaine patch in the immediate post-operative period following cesarean delivery. Additionally, a decrease in the use of opioids as pain control compared to patients that do not have a lidocaine patch in place the is anticipated.

Interventions

  • DRUG Lidocaine patch
  • OTHER Placebo patch

Study Locations (1)

Connecticut

  • Yale New Haven Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2021-10-10
Est. Completion 2022-08-31
Phase Phase 3

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04443569

The ClinicalTrials.gov registry entry for NCT04443569 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine patch is the first listed.

NCT04443569 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04443569 about?

NCT04443569 is a clinical study titled "Lidocaine Patches After Cesarean Section". The aim of this study is to investigate the impact of using lidocaine patches after cesarean section on pain control and opioid use in the immediate post-operative period. The hypothesis is the use of lidocaine patches in the immediate post-operative period will lead to a decrease in the visual anal...

What is the current status of trial NCT04443569?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2021-10-10. Estimated completion is 2022-08-31.

What conditions does trial NCT04443569 study?

This clinical trial studies the following conditions: Opioid Use, Postoperative Pain, Obstetric Pain.

What interventions are being tested in trial NCT04443569?

The interventions under investigation include: Lidocaine patch (DRUG), Placebo patch (OTHER).

Who is sponsoring clinical trial NCT04443569?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04443569 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.